Thursday, March 02, 2023 1:07:30 PM
Recent ATXI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:18:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:55:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:55:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:53:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:53:10 PM
- Avenue Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/03/2024 12:30:35 PM
- Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/13/2024 08:05:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:16:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:13:12 PM
- Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/09/2024 08:05:01 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/12/2024 08:09:03 PM
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 12:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:30:20 PM
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) • GlobeNewswire Inc. • 05/16/2024 12:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:01:25 PM
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/10/2024 08:53:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:52:35 PM
- Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds • GlobeNewswire Inc. • 04/29/2024 12:00:14 PM
- Avenue Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/24/2024 11:30:41 AM
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 • GlobeNewswire Inc. • 03/25/2024 12:30:00 PM
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/18/2024 08:05:14 PM
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq • GlobeNewswire Inc. • 03/15/2024 12:15:01 PM
- Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:00:17 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM